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ABSTRACT
Background: Apolipoprotein E (ApoE) plays a role in the regulation of lipid metabolism in humans. ApoE, a 
229-amino-acid polypeptide, is classified into three major isoforms (E2, E3, and E4) according to the differences 
in amino acids at positions 112 and 158. In the normal population, ApoE3 isoform is the most prevalent, and 
ApoE2 or E4 is frequently associated with hyperlipoproteinemia. The objective of this work was to investigate 
the relationship between ApoE gene polymorphism and coronary heart disease (CHD) in Gaza Strip and 
investigate the association between serum lipid levels and CHD.  Material and Methods: The study population 
consisted of 137 subjects including 69 CHD cases (45 male, 24 female) and 68 healthy subjects (33 male 
and 35 female). Results: The ApoE3/E3 genotype was the most common in the control and the CHD groups. 
ApoE2/E3 and ApoE3/E4 were the next most common genotypes. The frequencies of ApoE alleles in the CHD 
subjects were 0.826 for E3, 0.137 for E4, and 0.0362 for E2. These frequencies are comparable to those found 
in the control group which were 0.875 for the E3, 0.073 for E4, and 0.0515 for E2. No statistically significant 
differences in ApoE genotypes were found between the patients and the control groups. Moreover, there was no 
significant difference between the mean of triglyceride (TG) and HDL levels among different ApoE genotypes. 
However, there was a significant difference in the mean of LDL and ApoE genotypes where the mean of LDL 
was 218.17 mg/dl in ApoE4, 149.67 mg/dl in ApoE2, and 184.52 mg/dl in ApoE3. A significant difference was 
also evident between the mean of LDL levels in the CHD and the control group where the mean of LDL was 
126 mg/dl in CHD and 111.47 mg/dl in the control group. Our study indicated that there was no significant 
difference between the mean of cholesterol and TG levels of the CHD and the control groups. Conclusions: 
To our knowledge, this is the first study in Gaza Strip investigating the relation between ApoE genotypes and 
CHD. Further investigations are needed to link other genetic factors to CHD. 
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INTRODUCTION
Apolipoprotein E (ApoE) is a polymorphic protein codified 
by three alleles in the same locus. Variability in ApoE 
binding to ApoE or LDL receptors results in different 
levels of lipids and lipoproteins and risk of coronary 
heart disease (CHD) among individuals predisposed to   
CHD.[1] Cardiovascular diseases (CVDs), including CHD 
and stroke, are the most important causes of mortality 
and morbidity. The known risk factors affecting CHD will 
inevitably affect the relation of ApoE to CHD. Several 
studies have indicated that the classic cardiovascular risk 
factors including smoking, high blood pressure, low HDL 
cholesterol, and in most studies, also high total cholesterol 
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are important predictors of CHD events in elderly as well 
as middle-aged subjects. Lately, new cardiovascular risk 
factors such as apolipoproteins, including ApoE, have 
been a focus of keen investigation.[2] ApoE is an essential 
part of lipoprotein metabolism. It is present in lipoprotein 
particles and mediates lipoprotein binding to the LDL and 
lipoprotein remnant receptors. Defects in the ApoE protein 
could diminish its ability to bind to the receptors, which 
then leads to an elevated blood cholesterol level.[3] The gene 
coding for ApoE is located on chromosome 19 near the 
genes for Apo C-I and C-II. Three different alleles, E2, E3, 
and E4, account for ApoE polymorphism and determine 
the six genotypes E2/2, E2/3, E2/4, E3/3, E4/3, and 
E4/4.[2] ApoE polymorphisms have been associated with 
variations in the blood cholesterol level and with the risk 
of atherosclerosis and premature CVDs.[4]
ApoE polymorphism has functional effects on lipoprotein 
metabolism mediated through the hepatic binding, uptake, 
and catabolism of lipid particles, i.e., chylomicrons, 
chylomicron remnants, VLDL, and HDL subspecies. ApoE 
contributes to variability in normal cholesterol levels in 
populations.[5] 
The major effect of genetic variation at this locus is its 
influence on cholesterol levels, one of the major risk 
factors for CVDs, particularly coronary artery disease. With 
reference to cholesterol effects from the E3 allele, E4 is 
associated with higher total and low density lipoprotein 
cholesterol levels and E2 with lower levels. The cholesterol-
lowering effect of E2 tends to be greater than the 
cholesterol-raising effect of E4. In total, the contribution 
of this gene to cholesterol variability based on a variety 
of populations that have been studied is no more than 
10%. Diet and other genes contribute to each individual’s 
cholesterol level, as well as to the population’s average level. 
Many studies have looked at interactions with variants of 
this gene as possible modifiers of other cardiovascular risks, 
such as high- and low-fat diets and active versus sedentary 
lifestyles. Interactions with lipid-lowering medications have 
also been investigated in relation to ApoE.[6]
ApoE facilitates the binding of triglyceride (TG)-rich 
lipoprotein remnants to receptors that determine their 
clearance. The isoforms vary in their receptor-binding 
activity, with ApoE4 having the greatest receptor binding 
and ApoE2 having a decreased affinity. Individuals with 
ApoE2 have higher levels of TGs, and ApoE2 homozygotes 
have greatly increased concentrations of remnants, which 
frequently results in a form of dyslipidemia called type III 
or dysbetalipoproteinemia. Individuals with E4, conversely, 
tend to have higher concentrations of LDL cholesterol; 
this increase is due, in part, to more efficient absorption 
of dietary cholesterol and perhaps down-regulation of 
the LDL receptor. Thus, ApoE is an important candidate 
gene for CVD.[7] 
Approximately, 1% of individuals in the general population 
are ApoE2/2 homozygotes. However, only a small 
percentage (2–5%) of these ApoE2/2 homozygotes 
develop type III hyperlipoproteinemia. Utermann et al. 
suggested that homozygosity for ApoE2 is a necessary but 
insufficient genetic influence and that additional genetic or 
environmental factors are required for the expression of 
type III hyperlipoproteinemia in ApoE2/2 homozygotes. 
Until 1979, no other abnormalities in other genes had been 
identified.[8] High levels of total and LDL cholesterol and 
low levels of HDL cholesterol predispose individuals to 
the development of atherosclerosis. Serum levels of these 
lipids are partly determined by the ApoE genotype. With 
reference to ApoE3 homozygotes, ApoE2 is associated 
with lower levels of total and LDL cholesterol and with 
higher levels of HDL cholesterol, while ApoE4 has 
opposite effects. ApoE plays a pivotal role in the transport 
of lipoproteins and is involved in numerous processes in 
the arterial wall.[9] 
The risk of atherosclerosis and coronary heart disease 
in middle age appears to be higher in the presence of  the 
ApoE4 allele, possibly because of altered lipid metabolism. 
Not all studies, especially those of elderly subjects or 
survivors of heart attack, however, find an association 
between ApoE4 and CHD.[10] 
The ApoE4 allele (Arg-112 and Arg-158) has been linked 
to atherosclerosis. Individuals with E4/E4 genotype are at 
a higher risk of developing the disease.[11] 
The following were the objectives of this study
•  To investigate the association between ApoE gene 
polymorphism and CHD
•  To investigate the association between serum lipid levels 
and CHD 




This study is a retrospective case–control study in which 
ApoE genotyping was performed on 137 individuals who 
were randomly selected. Sixty-nine subjects (24 female and 
45 male) with coronary artery disease from Nasser Hospital 31 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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min at room temperature; then the mixture was centrifuged 
for 20 min at a speed of 2500 rpm; 0.1 ml of the clear 
supernatant was then transferred to the reaction solution 
for the determination of cholesterol.
The supernatant after the centrifugation should be clear; 
serum or plasma with TG contents ≥1000 mg/dl tends to 
produce a turbid supernatant or floating precipitates. In 
such case, the sample should be diluted 1:1 with the NaCl 
solution (0.9%) and then precipitation should be performed 
and the final result should be multiplied by 2.
LDL calculation 
LDL can be calculated from the parameters determined 
above using the following formula:
 LDL = Total cholesterol − (HDL + Triglyceride)       5
ApoE genotyping
DNA extraction
The human genomic DNA was isolated from the human 
blood sample by using the Promega kit(Promega, WI, USA). 
Then the quality of the isolated DNA was determined by 
running each sample on ethidium bromide-stained 1.0% 
agarose gel. 
PCR amplification of  the ApoE gene 
The primers used in the PCR forward Sequence   
ً5 to ً3 (TCCAAGGAGCTGCAGGCGGCGCA) reverse 
Sequence ً5 to ً3 (GCCCCGGCCTGGTACACTGCCA) 
Each PCR reaction mixture contained (~200 ng) of the 
prepared DNA template, 1× PCR buffer, 3.0 mM MgCl2, 
2.0 mM of each of the primers, and 200 mM of each 
deoxynucleotide triphosphate (dNTP); 1.25 U was the 
final concentration of Taq DNA polymerase (Promega) 
and DMSO (5%) in a thin-walled microfuge tube. The 
microfuge tubes were then placed in a thermal cycler and 
PCR amplification was done according to the following 
steps:
Step 1. Denaturation for 3 min at 95°C
Step 2. 40 cycles of
2.1. Melting for 60 s at 95°C
2.2. Annealing for 60 s at 58°C 
2.3. Extension for 90 s at 72°C
Step 3. Final elongation for 10 min at 72°C.
Upon the completion of PCR, the products were analyzed 
by electrophoresis on 2% ethidium bromide-stained 
agarose gel; then the 218-bp amplicons were stored at 4°C 
until analysis and digestion.
in Khan Younis  and 68 normal subjects were included in 
this study (35 female and 33 male). 
Sample collection 
Blood samples were collected from the patients and the 
control subjects after a 12- to 16-h overnight fasting. Each 
sample was collected into two tubes, one EDTA tube and 
one glass tube; the sample in the glass tube was separated 
serum was used for lipid profiling. The EDTA sample 
kept at 4°C was used within 24 h for DNA extraction and 
subsequent PCR analysis. 
Data analysis 
The data was entered, stored, and analyzed by a personal 
computer using the SPSS 8.0 statistical package. Differences 
in proportions were assessed by ANOVA, t-test, and chi-




10 µl Sample /standard was mixed1000 µl with reagent 
Cholesterol kit (DiaSys, Germany). The contents were 
mixed and incubated for 20 min at 20–25°C; then the 
absorbance of each tube was read at wavelength 500 nm 
against blank. The cholesterol content was then calculated 
by applying the following equation: 
Cholesterol (mg/dl) = Sample absorbance × Standard 
                                                  concentration. 
           Standard absorbance 
And the Triglyceride the same method but used the 
triglyceride kit (DiaSys, Germany) and in both method 
used the normal and high Cholesterol control (DiaSys, 
Germany), normal and high Triglyceride control (DiaSys, 
Germany).
HDL-C measurement 
HDL-cholesterol was measured after chylomicrons, VLDL, 
and LDL, were precipitated by adding phosphotungestic 
acid to the sample. Centrifugation afterward left only HDL 
in the supernatant. The HDL-C content was determined 
enzymatically using Ecoline S+ cholesterol as described 
below. 
Assay procedure 
The 200-µl serum samples were mixed with 500 µl of 
the precipitation reagent (phosphotungestic acid and 
magnesium chloride) and the mixture was incubated for 15 32 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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Restriction fragment length polymorphism analysis 
Genotyping for ApoE was performed by digesting the PCR 
product with restriction enzymes AflIII (5.000 U/ml) and 
HaeII (20.000 U/ml), 10× buffer, and 0.2 µl BSA. The 
contents were incubated for 24 h at 37°C. The digests were 
resolved on ethidium bromide-stained agarose gel and the 
results were documented by photography and separation 
of the resulting DNA fragments on agarose gel [Figure 1].
RESULTS
PCR results
The amplicon (PCR product) generated from the ApoE 
gene should yield a 218-bp-long double-stranded DNA 
fragment. A negative control (with water instead of the 
DNA template) was included in each reaction. The size of 
the amplicon was estimated by comparing it with a DNA 
molecular size marker (100 bp ladder DNA) run on the 
same gel.
Amplification product 
A representative photograph of the ApoE PCR amplification 
product is illustrated in Figure 2. Lane 1 in the figure shows 
the 100 bp ladder, lane 4 contains a negative control, and 
the other lanes show the 218 bp ApoE amplicon.
RFLP result 
Figure 3 illustrates a representative ApoE genotyping by 
AflIII (A) and HaeII (H) digestion of the 218 bp amplified 
fragment.
Genotype frequencies
The ApoE allele frequencies in the control subjects were 
5.15% for the E2 allele, 87.5% for the E3 allele, and 7.3% 
for the E4 allele. The frequencies in the CHD group were 
3.62% for the E2 allele, 82.6% for the E3 allele, and 13.77% 
for the E4 allele [Table 1].
Distribution of subjects according to ApoE genotypes 
The distribution of the subjects according to ApoE 
genotypes was as follows: 70.1% E3/E3, 21.2% E3/E4, 
Figure 1: A schematic diagram illustrating ApoE RFLP analysis
Figure 2: A photograph of the ApoE amplification product. Lane 1 
shows the 100 bp ladder, lane 4 negative control, and the rest of lanes 
show the 218 bp ApoE PCR product 
Figure 3: A representative photograph of AflIII (A) and HaeII (H) 
digestion of the ApoE 218 bp amplified fragment. M indicates the 100 
bp size marker. The digests were run on ethidium bromide-stained 3% 
agarose gel; E3 = 145 bp, E2 = 168 bp, E4 = 195 bp
and 8.8% E3/E2 
Relationship between CHD and ApoE gene 
polymorphism
The results showed that there was no statistically significant 
Table 1: Frequency of ApoE alleles among the case and 
the control groups
Alleles CHD group  Control group 
n Percentage n Percentage 
E3 114 82.60 119 87.5
E2 5 3.62 7 5.15
E4 19 13.77 10 7.35
Total 138 100 136 10033 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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relation between CHD and ApoE gene polymorphism (χ2 
= 3.4, P-value = 0.17), where the presence of the E3/E3 
genotype was the most frequent among cases and controls 
(65.2% and 75%, respectively) as shown in Table 2.
Relationship between the ApoE genotype and gender
The results showed that there was no statistically significant 
relation between the ApoE genotype and gender (χ2 = 3.39, 
P-value = 0.18; Table 3).
Relationship between CHD and lipid profile
There was no statistically significant difference between 
the means of cholesterol and TG levels between the CHD 
and the control groups (t = 1.3, P-value = 0.19 and t = 1.6, 
P-value = 0.1, respectively). On the other hand, there were 
significant differences between the mean of LDL and HDL 
levels between cases and controls (P-value = 0.02 and P < 
0.05, respectively).
Relationship between the lipid profile and ApoE 
genotypes 
The relationship between the lipid profile and ApoE is 
provided in Table 4. 
As shown in the table, there was no significant difference 
between the mean of cholesterol, TGs, and HDL regardless 
of the ApoE genotype. On the other hand, there was a 
significant difference between the ApoE genotype and the 
mean of LDL.
CHD and age
The results of the study showed that there was a statistically 
significant difference between the means of age of cases 
and controls (P-value < 0.05) where the mean age of cases 
was 57.65 years, while that of the controls was 44.01.
CHD and smoking 
The results of the study showed that there was a statistically 
significant difference between the smokers and nonsmokers 
in cases and controls (χ2 = 4.56, P-value = 0.049) as shown 
in Table 6.
DISCUSSION 
According to the results obtained from PCR–RFLP, the 
ApoE allele frequencies in the control group were 0.0515 
for the E2 allele, 0.875 for the E3 allele, and 0.073 for 
the E4 allele. This distribution is in agreement with the 
distribution in the control group reported in a Saudi 
study: 0.888 for E3, 0.050 for E2, and 0.062 for E4.[12] 
The frequencies of the ApoE alleles in the CHD subjects 
were 0.0362 for the E2 allele, 0.826 for the E3 allele, and 
0.1377 for the E4.
Table 3: Relationship between the ApoE gene and gender
Genotype  Male (n) Female (n) Total P-value
E3/E3 50 46 96 0.18
E3/E4 19 10 29
E3/E2 9 3 12
Total  78 59 137
Table 4: Relationship between CHD and lipid profile
Lipid profiles  Mean
CHD group  Control group  t-value P-value
Cholesterol (mg/dl)  193.6 183.49 1.3 0.19
Triglyceride (mg/dl) 133.86 116.94 1.6 0.1
LDL (mg/dl) 126 111.47 2.3 0.02
HDL (mg/dl) 39.70 49.94 4.11 0.000
Table 2: Distribution of the ApoE genotypes among the cases and the control groups
Genotype Case Control Total P-value
N Percentage n Percentage  n Percentage 
E3/E3 45 65.2 51 75 96 70.1 0.17
E3/E2 5 7.2 7 10.3 12 8.8
E3/E4 19 27.5 10 14.7 29 21.2
Total 69 100 68 100 137 10034 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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Relation between ApoE gene polymorphism and 
CHD
According to our results, it was found that 27.5% (19 of 
69) had E3/E4 in the CHD group as compared to 14.7% 
(10/68) of the control group. When compared to other 
studies, this percentage is close to that reported in Saudi 
Arabia where 20.8% of the CHD subjects had E3/E4 as 
compared to 12.5% from the control group.[12] Kolovou has 
shown that 21.8% of the CHD and 16.3% of the control 
group had the E3/E4 genotype.[13] The present study 
however indicated that there is no statistically significant 
relation between CHD and ApoE genes (χ2 = 3.4, P-value 
= 0.17). These results are in agreement with different 
studies such as the Saudi and the Taiwanese studies which 
recorded that no statistical difference in genotype or allelic 
distribution was found between the patients of CHD and 
the control groups.[12,13] These results can be explained by 
the fact that other genetic or environmental risk factors 
may interact with ApoE4 in determining the CHD risk. 
We did not find a significant difference for the ApoE gene 
and genotype frequencies between patients and controls, 
suggesting that the E4 allele is not a strong risk factor alone 
for CHD in Gaza Strip. For the E4 allele, a significantly 
increased frequency in patients compared to healthy 
controls has been described in some but not all studies 
and the E4 allele could be a risk factor in association with 
other genetic or environmental factors.[14]
CVD risk is influenced by several well-established risk 
factors, such as body mass index (BMI), an indicator of  
overweight and obesity, blood lipids, diabetes, and blood 
pressure. These are intermediate phenotypes, correlated 
among themselves and having their own genetic and 
environmental determinants, including diet, nutrition, 
hormones, smoking, alcohol intake, and physical activity.[15]
Serum lipid profile and the ApoE genotypes 
As we noted from our results, the mean of cholesterol 
level (218.17 mg/dl) was higher in subjects with the E4 
genotype as compared to those with E3 (184.5 mg/dl), 
while the E2 genotype had the lowest level (149.6 mg/
dl). These results confirm the effect of variation in the 
ApoE genotype on lipoprotein levels. The E4 allele has 
been shown to increase intestinal cholesterol absorption, 
to affect LDL synthesis in the liver, and to be associated 
with higher levels of total cholesterol and LDL-C and a 
higher prevalence of atherosclerosis. 
CHD and lipid profile
Our study results showed that there is a significant increase 
in LDL in the case group as compared to the control 
group. No statistically significant differences were evident 
between the mean of cholesterol between the case group 
and the control group. It has been suggested that LDL-C 
indicates the cardiovascular risk in individuals better than 
total cholesterol. This result is in agreement with other 
authors who reported that the most common lipid disorder 
was high TC and high LDL-C in CHD, which was much 
more prevalent than high TG. A high concentration of 
LDL must be considered the principal risk factor because 
in the absence of elevation of LDL-C, atherosclerosis 
develops slowly and usually remains subclinical. This is true 
even when the other independent risk factors are present.
CONCLUSION AND RECOMMENDATIONS
The present study focused on the detection of ApoE 
genotypes in Gaza Strip and the relationship between 
those genotypes and lipid profile in 69 cases of CHD from 
Nasser and AlShifa Hospitals as compared to 68 healthy 
subjects. The results of this study can be summarized as 
follows:
•  In Gaza Strip, the ApoE3/E3 genotype was the most 
common in the control and the CHD groups. ApoE2/
E3 and ApoE4/E3 were the next most common 
Table 5: Plasma lipid profile according to the ApoE 
genotype
Lipid (mg/dl) Genotype
E3/E3 E3/E4 E3/E2 P-value 
TC 184.52 218.17 149.67 0.8
TG 128.36 128.31 95.33 0.3
LDL 112.94 149.31 93.67 0.02
HDL 45.66 43.97 37.08 0.2
Table 6: Relationship between CHD and smokers
Subject  Smokers
Smokers  Nonsmokers  Total P-value
n Percentage  n Percentage  n Percentage
CHD 18 69.2 51 45.9 69 50.4 0.049
Control 8 30.8 60 54.1 68 49.6
Total  26 100 111 100 137 10035 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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genotypes. Other genotypes such as ApoE2/E2, 
ApoE4/E4, or ApoE2/E4 were not encountered in 
the examined subjects.
•  The frequencies of ApoE alleles in the CHD subjects 
were as follows: 0.826 for E3, 0.137 for E4, and 0.0362 
for E2. These frequencies are comparable to those 
found in the control group where we obtained the 
following results: 0.875 for E3, 0.073 for E4, and 0.0515 
for E2.
•  No statistically significant differences in ApoE 
genotypes were found between the patients and the 
control groups. 
•  The distribution of the ApoE genotypes in the Gaza 
Strip population was similar to that of other Asian 
populations.
•  Our study indicated that there was no significant 
difference between the mean of cholesterol and TG 
levels of the CHD and control groups.
•  There was a significant difference between the mean 
of LDL and HDL levels between the CHD and the 
control group. 
•  There was no significant difference between the 
mean of TGs and HDL between the different ApoE 
genotypes. However, there was a significant difference 
in the mean of LDL and ApoE genotypes. 
•  Smoking, hypertension, and advanced age are important 
risk factors for CHD. 
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